Aclarion

“Matching the right procedure to the right patient is what moves the field forward.” That’s how Dr. Todd Lanman describes the next step in spine care and why we're excited to welcome the Lanman Spinal Neurosurgery team to the CLARITY trial. Read: bit.ly/4neq5L5 $ACON

What if we could better identify the true source of chronic low back pain? Aclarion CEO Brent Ness joined @PlanetMicroCap to discuss how MR spectroscopy and AI-driven insights are advancing spine care and driving Nociscan adoption. Watch here: youtube.com/watch?v=ZH-uxq… $ACON

Aclarion has signed a second commercial agreement with Weill Cornell Medicine, bringing Nociscan into a prospective randomized controlled trial evaluating lumbar microdiscectomy and BMAC injection for degenerative disc disease. Read more: bit.ly/4wcpe1r $ACON

This morning, we announced Q1 2026 results, including triple-digit annual scan volume growth, advancement on reimbursement & clinical milestones, an expanding IP footprint & a strong balance sheet to support our long-term growth strategy. Read more: bit.ly/4ufa8q8 $ACON

We’re excited to announce the appointment of Dan Keefe to Aclarion as Commercial Director, Western U.S. Dan joins at an important time as we continue to build on our growing footprint and expand adoption of Nociscan. Read more: bit.ly/4cTlXvc $ACON

Aclarion announces a share repurchase program, reflecting confidence in the company. As we continue to drive adoption of Nociscan, we remain focused on disciplined capital allocation and delivering long-term value to shareholders. Read more: bit.ly/3OjrRh3 $ACON

Aclarion has secured a new U.S. patent covering the use of AI in future versions of its platform to further automate biomarker identification, supporting faster scalability and continued gross margin expansion. 64 issued & pending patents worldwide. bit.ly/4cvqYK4 $ACON

Thrilled to announce that Aclarion has received a Diamond Pinnacle Award for AI Innovation! This recognition reflects growing momentum behind Nociscan. Congrats to our team! Read more: bit.ly/4msN5p7 $ACON #PinnacleAwards

ICYMI: Nearly 100 Nociscans have now been performed at The London Clinic, reflecting growing real-world adoption in chronic low back pain evaluation. Dive into the release and testimonial video: bit.ly/4mgjC1r $ACON

New coverage from @BeckersSpine highlights clinical integration of Nociscan at Weill Cornell Medicine, adding the platform as part of a prospective spine study. ICYMI, read more: bit.ly/4tCSyMw $ACON

We’re looking forward to #ISASS2026. CEO, Brent Ness, and CSO, Ryan Bond, will be available for 1:1 meetings. If you would like to connect to discuss incorporating Nociscan into your practice, reach out to info@aclarion.com to schedule time. Hope to see you in Miami Beach! $ACON

Big news! Aclarion announced a commercial agreement with Weill Cornell Medicine, bringing Nociscan into a prospective study evaluating BMAC for osteoarthritis and degenerative disc disease, reflecting continued momentum in real-world care. Read more: bit.ly/3PSnx8R $ACON

Nearly 100 NOCISCANS have now been performed at The London Clinic! A new physician video highlights how NOCISCAN is being used in real-world practice to bring greater clarity and confidence to the evaluation of chronic low back pain. Watch bit.ly/4moF84j $ACON

Chronic low back pain can be difficult to evaluate. Aclarion is changing that. Through our first direct-to-consumer campaign in the UK, we are raising awareness of technologies like Nociscan that provide objective insight into pain. Explore: bit.ly/47eEboT $ACON

Aclarion CEO Brent Ness is addressing all things chronic back pain with @MrJeremyJackson on Sports Medicine Broadcast. He discusses how Nociscan provides physicians with additional insight when evaluating chronic low back pain. Tune in: bit.ly/4rKEwal $ACON

Today, Aclarion shared its latest shareholder update, highlighting: Advancing reimbursement discussions with regional U.S. payers Initial CLARITY trial readout expected in Q4 2026 Strong balance sheet with cash runway into 2028 Read more: bit.ly/3NdhOcR $ACON

Looking forward to the 38th Annual ROTH Conference! CEO Brent Ness will meet with investors to discuss Aclarion’s progress advancing Nociscan, upcoming 2026 catalysts and financial position. To schedule a 1:1 meeting: ksmith@pcgadvisory.com $ACON #ROTHConference2026 #ROTH

Aclarion CEO Brent Ness will be attending #LSIUSA26, March 16-20, 2026, in Dana Point, CA. He will be available for 1x1 meetings. Please email: ksmith@pcgadvisory.com to schedule. Read more: bit.ly/4rohohz $ACON

In a new interview, CEO Brent Ness discusses our approach to treating chronic lower back pain and highlights how Nociscan’s biomarker analysis helps identify painful discs to support better treatment planning. Subscribe for free: bit.ly/4rFLMFc $ACON

CEO Brent Ness offers perspective in @ODTmagazine, drawing an important parallel between cardiology’s evolution & what’s needed in spine care today. Read insights on how applying that same framework to chronic low back pain could improve outcomes: bit.ly/4cbVwSH $ACON